Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch PotentialSeeking Alpha • 02/13/26
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline UpdatesZacks Investment Research • 02/12/26
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 02/11/26
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't IgnoreThe Motley Fool • 02/11/26
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.The Motley Fool • 02/11/26
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling ShortSeeking Alpha • 02/05/26
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026PRNewsWire • 02/04/26
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?Zacks Investment Research • 01/27/26
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?The Motley Fool • 01/26/26
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key FactsZacks Investment Research • 01/22/26
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPRNewsWire • 01/12/26